questionsmedicales.fr
Facteurs biologiques
Protéines et peptides de signalisation intercellulaire
Éphrines
Éphrine A3
Éphrine A3 : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Éphrine A3 : Questions médicales les plus fréquentes",
"headline": "Éphrine A3 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Éphrine A3 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-21",
"dateModified": "2025-02-15",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Éphrine A3"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Éphrines",
"url": "https://questionsmedicales.fr/mesh/D036342",
"about": {
"@type": "MedicalCondition",
"name": "Éphrines",
"code": {
"@type": "MedicalCode",
"code": "D036342",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.529.500"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Éphrine A3",
"alternateName": "Ephrin-A3",
"code": {
"@type": "MedicalCode",
"code": "D036384",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Elena B Pasquale",
"url": "https://questionsmedicales.fr/author/Elena%20B%20Pasquale",
"affiliation": {
"@type": "Organization",
"name": "Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA. elenap@sbpdiscovery.org."
}
},
{
"@type": "Person",
"name": "Katsuaki Ieguchi",
"url": "https://questionsmedicales.fr/author/Katsuaki%20Ieguchi",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacology, Tokyo Women's Medical University, Tokyo, Japan. kieguchi@twmu.ac.jp."
}
},
{
"@type": "Person",
"name": "Yoshiro Maru",
"url": "https://questionsmedicales.fr/author/Yoshiro%20Maru",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacology, Tokyo Women's Medical University, Tokyo, Japan. maru.yoshiro@twmu.ac.jp."
}
},
{
"@type": "Person",
"name": "Stamatios Theocharis",
"url": "https://questionsmedicales.fr/author/Stamatios%20Theocharis",
"affiliation": {
"@type": "Organization",
"name": "First Department of Pathology, Medical School, National and Kapodistrian University of Athens, 157 72 Athens, Greece."
}
},
{
"@type": "Person",
"name": "Liu Yang",
"url": "https://questionsmedicales.fr/author/Liu%20Yang",
"affiliation": {
"@type": "Organization",
"name": "Department of Ophthalmology, Peking University First Hospital, Beijing, China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Network meta-analysis of sacubitril/valsartan for the treatment of essential hypertension.",
"datePublished": "2022-11-03",
"url": "https://questionsmedicales.fr/article/36326841",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00392-022-02120-0"
}
},
{
"@type": "ScholarlyArticle",
"name": "Effectiveness of different treatments for odontogenic keratocyst: a network meta-analysis.",
"datePublished": "2022-09-21",
"url": "https://questionsmedicales.fr/article/36150944",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ijom.2022.09.004"
}
},
{
"@type": "ScholarlyArticle",
"name": "Herbal Medicines for Rhinosinusitis: A Systematic Review and Network Meta-analysis.",
"datePublished": "2023-01-07",
"url": "https://questionsmedicales.fr/article/36609950",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s11882-022-01060-z"
}
},
{
"@type": "ScholarlyArticle",
"name": "Pregabalin administration in patients with fibromyalgia: a Bayesian network meta-analysis.",
"datePublished": "2022-07-15",
"url": "https://questionsmedicales.fr/article/35840702",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-022-16146-x"
}
},
{
"@type": "ScholarlyArticle",
"name": "Theory and practice of Bayesian and frequentist frameworks for network meta-analysis.",
"datePublished": "2022-06-27",
"url": "https://questionsmedicales.fr/article/35760451",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1136/bmjebm-2022-111928"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Facteurs biologiques",
"item": "https://questionsmedicales.fr/mesh/D001685"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines et peptides de signalisation intercellulaire",
"item": "https://questionsmedicales.fr/mesh/D036341"
},
{
"@type": "ListItem",
"position": 4,
"name": "Éphrines",
"item": "https://questionsmedicales.fr/mesh/D036342"
},
{
"@type": "ListItem",
"position": 5,
"name": "Éphrine A3",
"item": "https://questionsmedicales.fr/mesh/D036384"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Éphrine A3 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Éphrine A3",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-04",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Éphrine A3",
"description": "Comment diagnostiquer une anomalie d'éphrine A3 ?\nQuels examens sont recommandés pour évaluer l'éphrine A3 ?\nY a-t-il des biomarqueurs associés à l'éphrine A3 ?\nQuels symptômes peuvent indiquer un problème avec l'éphrine A3 ?\nPeut-on utiliser l'imagerie pour évaluer l'éphrine A3 ?",
"url": "https://questionsmedicales.fr/mesh/D036384?mesh_terms=Network+Meta-Analysis&page=5#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Éphrine A3",
"description": "Quels sont les symptômes d'une dysfonction d'éphrine A3 ?\nL'éphrine A3 est-elle liée à des maladies spécifiques ?\nComment l'éphrine A3 affecte-t-elle le système nerveux ?\nDes troubles comportementaux peuvent-ils être liés à l'éphrine A3 ?\nL'éphrine A3 influence-t-elle le développement cérébral ?",
"url": "https://questionsmedicales.fr/mesh/D036384?mesh_terms=Network+Meta-Analysis&page=5#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Éphrine A3",
"description": "Peut-on prévenir les troubles liés à l'éphrine A3 ?\nY a-t-il des facteurs environnementaux influençant l'éphrine A3 ?\nComment le mode de vie affecte-t-il l'éphrine A3 ?\nDes conseils nutritionnels peuvent-ils aider ?\nL'éducation prénatale peut-elle prévenir des troubles ?",
"url": "https://questionsmedicales.fr/mesh/D036384?mesh_terms=Network+Meta-Analysis&page=5#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Éphrine A3",
"description": "Quels traitements ciblent l'éphrine A3 ?\nPeut-on modifier l'expression de l'éphrine A3 ?\nY a-t-il des essais cliniques sur l'éphrine A3 ?\nQuels médicaments peuvent affecter l'éphrine A3 ?\nL'éphrine A3 peut-elle être une cible thérapeutique ?",
"url": "https://questionsmedicales.fr/mesh/D036384?mesh_terms=Network+Meta-Analysis&page=5#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Éphrine A3",
"description": "Quelles complications peuvent survenir avec l'éphrine A3 ?\nL'éphrine A3 est-elle impliquée dans des cancers ?\nDes troubles cognitifs peuvent-ils être des complications ?\nComment les complications sont-elles gérées ?\nY a-t-il des risques de récidive avec l'éphrine A3 ?",
"url": "https://questionsmedicales.fr/mesh/D036384?mesh_terms=Network+Meta-Analysis&page=5#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Éphrine A3",
"description": "Quels sont les facteurs de risque pour l'éphrine A3 ?\nL'hérédité joue-t-elle un rôle dans les troubles d'éphrine A3 ?\nLes toxines environnementales affectent-elles l'éphrine A3 ?\nLe stress peut-il influencer l'éphrine A3 ?\nY a-t-il des prédispositions génétiques pour l'éphrine A3 ?",
"url": "https://questionsmedicales.fr/mesh/D036384?mesh_terms=Network+Meta-Analysis&page=5#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une anomalie d'éphrine A3 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques et des analyses de tissus peuvent être utilisés pour détecter des anomalies."
}
},
{
"@type": "Question",
"name": "Quels examens sont recommandés pour évaluer l'éphrine A3 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'immunohistochimie et la PCR sont souvent utilisés pour évaluer l'expression de l'éphrine A3."
}
},
{
"@type": "Question",
"name": "Y a-t-il des biomarqueurs associés à l'éphrine A3 ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'éphrine A3 elle-même peut servir de biomarqueur dans certaines pathologies neurologiques."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un problème avec l'éphrine A3 ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles neurologiques ou des anomalies de développement peuvent indiquer un problème."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser l'imagerie pour évaluer l'éphrine A3 ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'imagerie cérébrale peut aider à visualiser des anomalies associées à des dysfonctionnements de l'éphrine A3."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une dysfonction d'éphrine A3 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent inclure des troubles cognitifs, des problèmes de coordination et des retards de développement."
}
},
{
"@type": "Question",
"name": "L'éphrine A3 est-elle liée à des maladies spécifiques ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des anomalies d'éphrine A3 sont associées à des maladies neurodégénératives et des cancers."
}
},
{
"@type": "Question",
"name": "Comment l'éphrine A3 affecte-t-elle le système nerveux ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle joue un rôle dans la formation des synapses et la plasticité neuronale, influençant le comportement."
}
},
{
"@type": "Question",
"name": "Des troubles comportementaux peuvent-ils être liés à l'éphrine A3 ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des dysfonctionnements de l'éphrine A3 peuvent entraîner des troubles du comportement."
}
},
{
"@type": "Question",
"name": "L'éphrine A3 influence-t-elle le développement cérébral ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle est essentielle pour le développement normal des circuits neuronaux dans le cerveau."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les troubles liés à l'éphrine A3 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention passe par une détection précoce et une intervention dans les cas à risque."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs environnementaux influençant l'éphrine A3 ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des facteurs environnementaux comme la nutrition et les toxines peuvent influencer son expression."
}
},
{
"@type": "Question",
"name": "Comment le mode de vie affecte-t-il l'éphrine A3 ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain peut favoriser une expression normale de l'éphrine A3 et réduire les risques."
}
},
{
"@type": "Question",
"name": "Des conseils nutritionnels peuvent-ils aider ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée riche en nutriments peut soutenir la santé neuronale et l'éphrine A3."
}
},
{
"@type": "Question",
"name": "L'éducation prénatale peut-elle prévenir des troubles ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'éducation prénatale sur les risques environnementaux peut aider à prévenir des troubles liés à l'éphrine A3."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent l'éphrine A3 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des thérapies géniques et des médicaments ciblant les voies de signalisation peuvent être envisagés."
}
},
{
"@type": "Question",
"name": "Peut-on modifier l'expression de l'éphrine A3 ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des approches pharmacologiques peuvent moduler l'expression de l'éphrine A3 dans certaines conditions."
}
},
{
"@type": "Question",
"name": "Y a-t-il des essais cliniques sur l'éphrine A3 ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des essais cliniques sont en cours pour évaluer des traitements ciblant l'éphrine A3 dans diverses pathologies."
}
},
{
"@type": "Question",
"name": "Quels médicaments peuvent affecter l'éphrine A3 ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains médicaments anticancéreux et neuroprotecteurs peuvent influencer l'activité de l'éphrine A3."
}
},
{
"@type": "Question",
"name": "L'éphrine A3 peut-elle être une cible thérapeutique ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, en raison de son rôle dans diverses maladies, elle est considérée comme une cible thérapeutique potentielle."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec l'éphrine A3 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications neurologiques et des troubles de développement peuvent survenir en cas d'anomalies."
}
},
{
"@type": "Question",
"name": "L'éphrine A3 est-elle impliquée dans des cancers ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des anomalies d'éphrine A3 sont associées à certains types de cancers, notamment le gliome."
}
},
{
"@type": "Question",
"name": "Des troubles cognitifs peuvent-ils être des complications ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des dysfonctionnements de l'éphrine A3 peuvent entraîner des troubles cognitifs sévères."
}
},
{
"@type": "Question",
"name": "Comment les complications sont-elles gérées ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion des complications implique des traitements symptomatiques et des interventions ciblées."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de récidive avec l'éphrine A3 ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des risques de récidive peuvent exister dans les cas de cancers associés à des anomalies d'éphrine A3."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour l'éphrine A3 ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs génétiques, environnementaux et le mode de vie peuvent influencer le risque d'anomalies."
}
},
{
"@type": "Question",
"name": "L'hérédité joue-t-elle un rôle dans les troubles d'éphrine A3 ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de troubles neurologiques peuvent augmenter le risque d'anomalies."
}
},
{
"@type": "Question",
"name": "Les toxines environnementales affectent-elles l'éphrine A3 ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à certaines toxines peut perturber l'expression de l'éphrine A3."
}
},
{
"@type": "Question",
"name": "Le stress peut-il influencer l'éphrine A3 ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut affecter la signalisation de l'éphrine A3 et la santé neuronale."
}
},
{
"@type": "Question",
"name": "Y a-t-il des prédispositions génétiques pour l'éphrine A3 ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines variations génétiques peuvent prédisposer les individus à des troubles liés à l'éphrine A3."
}
}
]
}
]
}
Sacubitril/valsartan has been demonstrated to reduce blood pressure in hypertensive patients, but the best dose remains unclear. We performed this network meta-analysis to determine the comparative ef...
We searched four databases for relevant studies published before January 2022. Mean systolic and diastolic blood pressures in the sitting position (msSBP and msDBP) and ambulatory condition (24-h maSB...
In hypertensive patients, 200 mg once daily of sacubitril/valsartan may exert a greater reduction in ambulatory blood pressure than 100 mg once daily and 200 mg once daily may not be inferior to 400 m...
Odontogenic keratocysts (OKC) are benign but aggressive lesions. As there is a lack of well randomized clinical studies assessing the effectiveness of the different treatment options for OKC, a networ...
To analyze and compare the effects of herbal medicines (HMs) for treating different forms of rhinosinusitis....
Forty-seven randomized controlled trials evaluating 18 HMs in six different rhinosinusitis populations were included in the network meta-analysis. Certainty of evidence was assessed using the Grading ...
PROSPERO ID: CRD42022328265 May 10, 2022....
Several studies investigated the effectiveness and the safety of different doses of pregabalin in fibromyalgia. However, the optimal protocol remains controversial. A Bayesian network meta-analysis co...
Network meta-analysis (NMA) is an increasingly popular statistical method of synthesising evidence to assess the comparative benefits and harms of multiple treatments in a single analysis. Several aut...
There are limited pooled data showing the impact of visceral metastasis on oncologic outcomes in metastatic prostate cancer patients treated with combination systemic therapies. We aimed to analyze an...
Three databases were queried in July 2022 for randomized, controlled trials analyzing metastatic prostate cancer patients treated with combination systemic therapy (androgen receptor signaling inhibit...
Overall, 12 and 8 randomized, controlled trials were included for systematic review and meta-analyses/network meta-analyses, respectively. In metastatic hormone-sensitive prostate cancer patients, add...
Despite aggressive clinical behavior and worse trajectory of metastatic hormone-sensitive prostate cancer and metastatic castration-resistant prostate cancer with visceral metastasis, the effectivenes...
Although aggregate data (AD) from randomised clinical trials (RCTs) are used in the majority of network meta-analyses (NMAs), other study designs (e.g., cohort studies and other non-randomised studies...
We developed the R package crossnma to perform cross-format (IPD and AD) and cross-design (RCT and NRS) NMA and network meta-regression (NMR). The models are implemented as Bayesian three-level hierar...
The R package crossnma enables the user to perform NMA and NMR with different data types in a Bayesian framework and facilitates the inclusion of all types of evidence recognising differences in risk ...
Appendicectomy remains the standard treatment for appendicitis. There is a lack of clarity on the timeframe in which surgery should be performed to avoid unfavourable outcomes....
To perform a systematic review and network meta-analysis to evaluate the impact the (1)time-of-day surgery is performed (2), time elapsed from symptom onset to hospital presentation (patient time) (3)...
A systematic review was performed as per PRISMA-NMA guidelines. The time-of-day which surgery was done was divided into day, evening and night. The other groups were divided into < 24 h, 24-48 h and >...
Sixteen studies were included with a total of 232,678 patients. The time of day at which surgery was performed had no impact on outcomes. The incidence of complicated appendicitis, post-operative comp...
Appendicectomy within 24 h of hospital admission is associated with improved outcomes compared to patients having surgery 24-48 and > 48 h after admission. The time-of-day which surgery is performed d...
Preeclampsia (PE) is a pregnancy disorder that represents a major cause of maternal and perinatal morbidity and mortality....
This network meta-analysis was registered with PROSPERO. We searched the PubMed, ClinicalTrials.gov. and Embase databases for studies published from inception to the 31...
We included eight randomized controlled trials (RCTs) involving a total of 1192 women with PE; two studies were of high quality and six were of moderate quality. Eight interventions were addressed in ...
According to the eight RCTs included in this study, Diltiazem was the most effective in reducing blood pressure in PE patients; Labetalol and Nicardipine also had good effects. Diltiazem is preferred ...
The aims of this study were to systematically review the literature and compare the relative effects of various luting agents on bonding between glass-fiber posts and root canal dentin in short- and l...
The literature was electronically searched in PubMed, Embase, and Scopus. A manual search was performed by scanning the reference lists of the included studies....
Two reviewers independently conducted the selection of studies, data extraction, and risk of bias assessment. Pairwise meta-analyses were based on random effect models. Network meta-analyses were cond...
One hundred and eighteen studies were included and assessed the effects of five luting agents. For pairwise meta-analyses, in short-term aging conditions, a significantly higher bond strength of self-...
The SARC tended to be the most effective luting agent in bonding between glass-fiber posts and root canal dentin in short- and long-term aging conditions....